Traders sold shares of Eli Lilly and Company (NYSE:LLY) on strength during trading hours on Friday. $51.44 million flowed into the stock on the tick-up and $80.70 million flowed out of the stock on the tick-down, for a money net flow of $29.26 million out of the stock. Of all companies tracked, Eli Lilly and had the 26th highest net out-flow for the day. Eli Lilly and traded up $1.38 for the day and closed at $82.92

LLY has been the topic of several analyst reports. Piper Jaffray Companies reiterated a “buy” rating and set a $103.00 target price on shares of Eli Lilly and in a research report on Thursday, August 31st. BMO Capital Markets reiterated a “sell” rating and set a $73.00 target price on shares of Eli Lilly and in a research report on Friday, August 4th. Jefferies Group LLC reiterated a “buy” rating and set a $89.00 target price (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Leerink Swann reiterated a “hold” rating on shares of Eli Lilly and in a research report on Thursday, August 31st. Finally, TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Hold” and a consensus target price of $87.97.

The stock has a market cap of $87.48 billion, a PE ratio of 35.88 and a beta of 0.34. The stock has a 50 day moving average of $81.04 and a 200 day moving average of $82.03.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same period in the prior year, the company posted $0.86 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.51%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is currently 90.04%.

In related news, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the transaction, the insider now directly owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now directly owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 826,900 shares of company stock worth $68,610,132. Corporate insiders own 0.20% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. M Holdings Securities Inc. purchased a new position in Eli Lilly and in the 2nd quarter valued at about $234,000. Achmea Investment Management B.V. lifted its stake in Eli Lilly and by 70.6% in the 2nd quarter. Achmea Investment Management B.V. now owns 54,884 shares of the company’s stock valued at $4,515,000 after buying an additional 22,714 shares in the last quarter. Aldebaran Financial Inc. lifted its stake in Eli Lilly and by 16.7% in the 2nd quarter. Aldebaran Financial Inc. now owns 5,950 shares of the company’s stock valued at $490,000 after buying an additional 850 shares in the last quarter. RNC Capital Management LLC lifted its stake in Eli Lilly and by 6.6% in the 2nd quarter. RNC Capital Management LLC now owns 452,866 shares of the company’s stock valued at $37,271,000 after buying an additional 28,133 shares in the last quarter. Finally, Sentry Investment Management LLC lifted its stake in Eli Lilly and by 0.7% in the 2nd quarter. Sentry Investment Management LLC now owns 77,668 shares of the company’s stock valued at $6,392,000 after buying an additional 506 shares in the last quarter. 75.77% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Traders Sell Eli Lilly and Company (LLY) on Strength (LLY)” was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/08/traders-sell-eli-lilly-and-company-lly-on-strength-lly-2.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.